First post, mainly to express an appreciation of the
First post, mainly to express an appreciation of the monitors of this board for creating a decent forum for discussion and sharing. I come from a medical background and am also grateful for the considerable infusion of insight from the likes of ohm20 and others which confirm for me how special this molecule is, sitting at the nexus of a multitude of inflammatory and immune-mediated processes. Equally startling to me is the paucity of side effects, which are the nemesis of so many pharmacological therapies.
A finance professor I had years ago said that true value always wins out in the end, so I continue to wait with the rest of us that know the value of what we own. I am amazed at the headwinds this company has faced, but they have persisted and to borrow a line from Calvin Coolidge, persistence alone is omnipotent. The incessant waves of short dumps have been met with buying by myself and others that are clear on the value, so ownership is also moving inexorably toward holders with conviction. I believe the radio silence portends a binary event which more likely than not will accrue to the benefit of those who see the value in a platform molecule and I am not the least bit surprised this is taking time…this is not a one trick pony but a diamond that has to be looked at from many different angles to properly inform any discussion of partnership or buyout.
As I wait in the silence for news I am hopeful Brazil answers out of left field and is able to help finally get this drug into the hands of clinicians, which is way overdue. I share the sentiment of many here that at this point it is beyond money and is a moral imperative if we can take death off the table for critical covid19. The failure of regulatory agencies to act like we are on a war footing with the virus, the catatonic (or adversarial) response to Leronlimab with no safety signal but repeated demonstration of impact has contributed to the hollowing out of the ranks of seasoned health care providers who are leaving the system in large numbers from exhaustion. Like loved ones that have been lost in the pandemic, they are not so readily replaced.
32
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Enterprise AI has reached the awkward stage where a slick chatbot demo no longer cuts it. GIGABYTE used its November 13 AI Partner Summit at the Pacific Palms Resort to make a more grounded pitch: companies need hardware and software setups that can put AI agents to work without casually tossing proprietary information into somebody else’s cloud. That is a sensible...
Continue Reading
A $166 million average book is not a cute training-program statistic. It says SEIA’s advisors aged 30 to 39 are already carrying serious client responsibility, and that matters because the registered investment advisory business is headed into a succession crunch nobody can solve with a glossy recruiting brochure. You Cannot Hand Off Trust Like a Spare Key Clients may...
Continue Reading
Desert acreage and a moon-landing backstory make for a handsome pitch, but Nevada is still standing at the starting line. The state has submitted its official response to NASA’s Request for Information for a proposed United States Space Academy, and the new promotional video is meant to show why the Silver State belongs in the conversation. Fair enough. There is real...
Continue Reading
November delivered a nasty little truth serum for Tessera Defense and Homeland Security: exchange status is not a cosmetic detail when the stock’s selling price has collapsed. On November 10, NYSE Regulation suspended trading in the company’s common shares on NYSE American and began delisting proceedings. By November 17, Tessera had a chance to request review by the...
Continue Reading
Some business awards are wallpaper; this one carries real clinical weight. EY US named Craig Chambliss, CEO and co-founder of Neurelis, its Entrepreneur Of The Year 2026 National Overall Award winner. In a sector where plenty of companies talk grandly about changing lives and then vanish into the regulatory fog, the underlying story matters more than the trophy. Neurelis...
Continue Reading
Three proposed takeovers, three very different headaches, and one familiar question that never gets old: are regular shareholders actually receiving the best available deal? On Nov. 20, 2026, investor-rights law firm Halper Sadeh LLC said it was investigating the proposed transactions involving Penske Automotive Group, Werewolf Therapeutics and Personalis for potential...
Continue Reading
A Refinancing With Some Actual Breathing Room Metal cans may be boring, but a debt wall arriving in 2028 is not—and Ardagh Metal Packaging has moved that problem down the road. AMP priced €1.3 billion of senior secured floating-rate green notes on November 20, 2026. The proceeds are earmarked to redeem $600 million of senior secured green notes due in 2028 and €450...
Continue Reading
Chemicals buried in a cheap handbag or kids' accessory can wreck a marketplace's credibility faster than any glossy campaign can repair it. That is the uncomfortable backdrop to SHEIN and SPEAC's November 19 session on EU chemical-safety rules for marketplace sellers. This was not a fashion trend webinar; it was a practical warning about high-risk substances, regulatory...
Continue Reading
Church software has spent too many years behaving like a junk drawer, and Subsplash is plainly trying to replace it with one working system. The company used its November 18 Product Event in Dallas to show off releases from 2026 and preview two additions: Communications, due in December, and Subsplash Intelligence, targeted for early 2027. A Serious Push Beyond the Church...
Continue Reading
America’s digital plumbing is getting squeezed at both ends: the public connections nobody notices until they fail, and the industrial-scale computing boom everybody suddenly wants built yesterday. Connected Nation’s two bonus podcast episodes from the Broadband Nation Expo in New Orleans put those pressures side by side, and it is a more useful pairing than it may...
Continue Reading
Top 5 Most Recently Viewed Articles
Planning for a Comfortable Retirement with $1 Million Reaching the milestone of having $1 million saved in your IRA as you near your 70th birthday is a commendable accomplishment. However, to make sure this amount lasts throughout your retirement, which could extend over two decades, careful planning is essential. Effectively managing your retirement funds requires a good...
Continue Reading
Wells Fargo Downgrades SailPoint Technologies Holdings Wells Fargo has recently revised its stance on SailPoint Technologies Holdings (NYSE: SAIL), changing its investment rating from Overweight to Equalweight. Alongside this rating downgrade, the bank has also lowered its price target for the stock from $17 to $15. This shift indicates a more reserved outlook on the...
Continue Reading
Promising Phase 1 Metallurgical Results from Brunswick Exploration Brunswick Exploration Inc. (TSX-V: BRW; OTCQB: BRWXF; Frankfurt: 1XQ) has exciting developments regarding its Mirage Project. The Montreal-based mineral exploration company is charting a significant course in extracting lithium through innovative methodologies. Recent preliminary metallurgical results from...
Continue Reading
The Global Healthy Living Foundation Australia (GHLF Australia) forged a partnership with The Bone Bus back then, aiming to pump up bone health access in rural spots where folks were really struggling. This initiative wasn't just some PR stunt; it targeted real issues surrounding osteoporosis that so many older Australians faced. Rural Access: A Tough Nut to Crack Let’s...
Continue Reading
Kotak Securities slammed the brakes on any bullish sentiment around Larsen & Toubro Ltd. (LT:IN) back in late 2024, despite raising their price target from INR3,150 to INR3,380. Now, this sounds like good news on paper—a bit of upward adjustment—but let’s not kid ourselves here. They slapped a Sell rating on it right alongside that shiny new number. What gives?...
Continue Reading